nach oben

Current Pediatrics Reports

Erschienen in:

01.12.2021 | Critical Care (R Pierce, Section Editor)

Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children

verfasst von: Laura A. Vella, Anne H. Rowley

Erschienen in: Current Pediatrics Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We highlight the new clinical entity multisystem inflammatory syndrome in children (MIS-C), the progress in understanding its immunopathogenesis, and compare and contrast the clinical and immunologic features of MIS-C with Kawasaki disease (KD).

Recent Findings

Studies show immune dysregulation in MIS-C including T lymphocyte depletion and activation, T cell receptor Vbeta skewing, elevated plasmablast frequencies, increased markers of vascular pathology, and decreased numbers and functional profiles of antigen-presenting cells.

Summary

MIS-C is a late manifestation of infection with SARS-CoV-2 associated with marked immune activation and many potential mechanisms of immunopathogenesis. MIS-C and KD have clinical similarities but are distinct. Myocardial dysfunction with or without mild coronary artery dilation can occur in MIS-C but generally corrects within weeks. In contrast, the coronary arteries are the primary target in KD, and coronary artery sequelae can be lifelong. Supportive care and anti-inflammatory therapy appear to hasten improvement in children with MIS-C, and there is hope that vaccines will prevent its development.

• Bailey LC, Razzaghi H, Burrows EK, et al (2021) Assessment of 135794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr 175:176–184. Reports a lack of association between MIS-C and KD diagnoses.

•Whittaker E, Bamford A, Kenny J, et al (2020) Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. https://doi.org/10.1001/jama.2020.10369. Describes clinical features of children in Europe with MIS-C early in the pandemic.

• Godfred-Cato S, Bryant B, Leung J, et al (2020) COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 69:1074–1080. Analyzes clinical differences between acute COVID-19 and MIS-C.

Feldstein LR, Rose EB, Horwitz SM, et al (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. https://doi.org/10.1056/NEJMoa2021680. Reports clinical features of children in the USA with MIS-C.

• Campbell JI, Roberts JE, Dubois M, Naureckas Li C, Sandora TJ, Lamb GS (2021) Non-SARS-CoV-2 infections among patients evaluated for MIS-C associated with COVID-19. Pediatr Infect Dis J 40:e90–e93. Demonstrates the wide differential diagnosis of MIS-C.

Roberts JE, Campbell JI, Gauvreau K, Lamb GS, Newburger J, Son MB, Dionne A (2021) Differentiating multisystem inflammatory syndrome in children: a single-centre retrospective cohort study. Arch Dis Child. https://doi.org/10.1136/archdischild-2021-322290

••Belay ED, Abrams J, Oster ME, et al (2021) Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2021.0630. Describes the epidemiology of MIS-C in the USA and its relationship to COVID-19 outbreaks.

••Vella LA, Giles JR, Baxter AE, et al (2021) Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol. https://doi.org/10.1126/sciimmunol.abf7570. Provides a comprehensive analysis of immune dysregulation in MIS-C with adult and pediatric COVID-19 comparisons.

Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. 2021;4:e2116420.CrossRef

10.

Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450–6.CrossRef

11.

Davogustto GE, Clark DE, Hardison E, Yanis AH, Lowery BD, Halasa NB, Wells QS. Characteristics associated with multisystem inflammatory syndrome among adults with SARS-CoV-2 infection. JAMA Netw Open. 2021;4:e2110323.CrossRef

12.

•• Consiglio C, Cotugno N (2020) The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183(4) 968-981. Reports immunologic features of MIS-C and potential differences with those of KD.

13.

•• Carter MJ, Fish M, Jennings A, et al (2020) Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 26:1701–1707. Robust longitudinal immunophenotyping in MIS-C.

14.

•• Gruber CN, Patel RS, Trachtman R, et al (2020) Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 183:982–995.e14. High-dimensional immunophenotyping in MIS-C.

15.

• Ramaswamy A, Brodsky NN, Sumida TS, et al (2021) Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 54:1083–1095.e7. Single-cell immunophenotyping of MIS-C and evidence of Vbeta skewing.

16.

• Moreews M, Le Gouge K, Khaldi-Plassart S, et al (2021) Polyclonal expansion of TCR Vbeta 21.3 CD4 and CD8 T cells is a hallmark of multisystem inflammatory syndrome in children. Sci Immunol. https://doi.org/10.1126/sciimmunol.abh1516. Identifies and phenotypes cells with skewing of T cell receptor usage in MIS-C with COVID-19 and Kawasaki disease controls.

17.

• Diorio C, Henrickson SE, Vella LA, et al (2020) Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. J Clin Invest 130:5967–5975. Describes immunologic features differentiating acute COVID-19 from MIS-C.

18.

•Pierce CA, Preston-Hurlburt P, Dai Y, et al (2020) Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abd5487. Robust serologic data with comparisons to adult and pediatric COVID-19.

19.

•Porritt RA, Paschold L, Rivas MN, et al (2021) HLA class I–associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J Clin Invest. https://doi.org/10.1172/JCI146614. Demonstrates Vbeta skewing in MIS-C with febrile controls.

20.

• Diorio C, Shraim R, Vella LA, et al (2021) Proteomic profiling of MIS-C patients reveals heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. medRxiv. https://doi.org/10.1101/2021.04.13.21255439. Broad proteomic profiling in MIS-C vs COVID-19 that identifies elevation of PLA2G2A in MIS-C.

21.

Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130:5942–50.CrossRef

22.

Rodriguez-Smith JJ, Verweyen EL, Clay GM, et al (2021) Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(21)00139-9

23.

Kuypers FA, Rostad CA, Anderson EJ, et al (2021) Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). Exp Biol Med 15353702211028560

24.

Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020;324:294–6.CrossRef

25.

Lee PY, Platt CD, Weeks S, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020;146:1194-1200.e1.CrossRef

26.

Chou J, Platt CD, Habiballah S, et al (2021) Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.06.024

27.

Pérez-Gómez A, Vitallé J, Gasca-Capote C, et al (2021) Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. https://doi.org/10.1038/s41423-021-00728-2

28.

Hall MW. Immune modulation in pediatric sepsis. Pediatr Crit Care Med. 2019;8:42–50.

29.

Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640–8.CrossRef

30.

Anderson EM, Diorio C, Goodwin EC, et al (2020) SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. J Pediatric Infect Dis Soc. https://doi.org/10.1093/jpids/piaa161

31.

Rostad CA, Chahroudi A, Mantus G, et al (2020) Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics. https://doi.org/10.1542/peds.2020-018242

32.

Bartsch YC, Wang C, Zohar T, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021;27:454–62.CrossRef

33.

McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112:4719–24.CrossRef

34.

Wrammert J, Onlamoon N, Akondy RS, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol. 2012;86:2911–8.CrossRef

35.

Wec AZ, Haslwanter D, Abdiche YN, et al. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proc Natl Acad Sci U S A. 2020;117:6675–85.CrossRef

36.

Nash MC, Shah V, Reader JA, Dillon MJ. Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol. 1995;34:882–7.CrossRef

37.

Guzman J, Fung M, Petty RE. Diagnostic value of anti-neutrophil cytoplasmic and anti-endothelial cell antibodies in early Kawasaki disease. J Pediatr. 1994;124:917–20.CrossRef

38.

Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22:25–31.CrossRef

39.

Sharma H, Smith D, Turner CE, Game L, Pichon B, Hope R, Hill R, Kearns A, Sriskandan S (2018) Clinical and molecular epidemiology of staphylococcal toxic shock syndrome in the United Kingdom. Emerg Infect Dis. https://doi.org/10.3201/eid2402.170606

40.

Cheng MH, Zhang S, Porritt RA, Noval Rivas M, Paschold L, Willscher E, Binder M, Arditi M, Bahar I. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci U S A. 2020;117:25254–62.CrossRef

41.

Yonker LM, Gilboa T, Ogata AF, et al (2021) Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. https://doi.org/10.1172/JCI149633

42.

McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.CrossRef

43.

Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D’Antiga L (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. https://doi.org/10.1016/S0140-6736(20)31103-X

44.

Ouldali N, Pouletty M, Mariani P, et al (2020) Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health. https://doi.org/10.1016/S2352-4642(20)30175-9

45.

Bar-Meir M, Guri A, Godfrey ME, Shack AR, Hashkes PJ, Goldzweig O, Megged O. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep. 2021;11:13840.CrossRef

46.

Kim Y-J, Park H, Choi YY, Kim YK, Yoon Y, Kim K-R, Choi EH (2020) Defining association between COVID-19 and the multisystem inflammatory syndrome in children through the pandemic. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2020.35.e204

47.

Iio K, Uda K, Hataya H, Yasui F, Honda T, Sanada T, Yamaji K, Kohara M, Itokawa M, Miura M. Kawasaki disease or Kawasaki-like disease: influence of SARS-CoV-2 infections in Japan. Acta Paediatr. 2021;110:600–1.CrossRef

48.

Shulman S, Geevarghese B, Kim KY, Rowley A (2021) The impact of social distancing for COVID-19 upon diagnosis of Kawasaki disease. J Pediatric Infect Dis Soc. https://doi.org/10.1093/jpids/piab013

49.

••Kang JM, Kim YE, Huh K, Hong J, Kim DW, Kim MY, Jung SY, Kim JH, Jung J, Ahn JG (2021) Reduction in Kawasaki disease after nonpharmaceutical interventions in the COVID-19 era: a nationwide observational study in Korea. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.121.054785. Reports the decrease in KD diagnoses across Korea during COVID mitigation strategies.

50.

Iio K, Matsubara K, Miyakoshi C, Ota K, Yamaoka R, Eguchi J, Matsumura O, Okutani T, Ueda I, Nishiyama M. Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan. BMJ Paediatr Open. 2021;5:e001034.CrossRef

51.

Ae R, Shibata Y, Kosami K, Nakamura Y, Hamada H (2021) Kawasaki disease and pediatric infectious diseases during the coronavirus disease 2019 pandemic. J Pediatr. https://doi.org/10.1016/j.jpeds.2021.07.053

52.

Rowley AH, Baker SC, Arrollo D, et al. A protein epitope targeted by the antibody response to Kawasaki disease. J Infect Dis. 2020;222:158–68.CrossRef

53.

••Farooqi KM, Chan A, Weller RJ, et al (2021) Longitudinal outcomes for multisystem inflammatory syndrome in children. Pediatrics. https://doi.org/10.1542/peds.2021-051155. Describes generally excellent outcomes for children with MIS-C.

54.

•• Feldstein LR, Tenforde MW, Friedman KG, et al (2021) Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325:1074–1087. Describes generally excellent outcomes for children with MIS-C, including the lack of giant aneurysms.

55.

Binstadt BA, Levine JC, Nigrovic PA, Gauvreau K, Dedeoglu F, Fuhlbrigge RC, Weindling SN, Newburger JW, Sundel RP. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics. 2005;116:e89-93.CrossRef

56.

Muniz JC, Dummer K, Gauvreau K, Colan SD, Fulton DR, Newburger JW. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013;6:239–44.CrossRef

57.

Tsuda E, Hashimoto S. Time course of coronary artery aneurysms in Kawasaki disease. J Pediatr. 2021;230:133-139.e2.CrossRef

58.

Orenstein JM, Shulman ST, Fox LM, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One. 2012;7:e38998.CrossRef

59.

Duarte-Neto AN, Caldini EG, Gomes-Gouvêa MS, et al. An autopsy study of the spectrum of severe COVID-19 in children: from SARS to different phenotypes of MIS-C. EClinicalMedicine. 2021;35:100850.CrossRef

60.

Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19. Ann Intern Med. 2020;173:1025–7.CrossRef

61.

Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pediatr. 2018;6:374.CrossRef

62.

Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr. 2007;19:71–4.CrossRef

63.

Rowley AH, Wylie KM, Kim KY, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015;16:1076.CrossRef

64.

Pierce CA, Sy S, Galen B, Goldstein DY, Orner E, Keller MJ, Herold KC, Herold BC (2021) Natural mucosal barriers and COVID-19 in children. JCI Insight. https://doi.org/10.1172/jci.insight.148694

65.

Belhadjer Z, Auriau J, Méot M, Oualha M, Renolleau S, Houyel L, Bonnet D. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142:2282–4.CrossRef

66.

Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–64.CrossRef

67.

• Son MBF, Murray N, Friedman K, et al (2021) Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med 385:23–34. The above 3 studies report more rapid improvement in children with MIS-C treated with corticosteroid therapy.

68.

McArdle AJ, Vito O, Patel H, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385:11–22.CrossRef

69.

V Vukomanovic S Krasic S Prijic S Ninic S Popovic G Petrovic S Ristic R Simic I CerovicD Nesic 2021 Recent experience: corticosteroids as a first-line therapy in children with multisystem inflammatory syndrome and COVID-19-related myocardial damage Pediatr Infect Dis J https://doi.org/10.1097/INF.0000000000003260

Titel: Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children
verfasst von: Laura A. Vella
Anne H. Rowley
Publikationsdatum: 01.12.2021
Verlag: Springer US
Erschienen in: Current Pediatrics Reports / Ausgabe 4/2021
Elektronische ISSN: 2167-4841
DOI: https://doi.org/10.1007/s40124-021-00257-6

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Reanimation bei Kindern – besser vor Ort oder während Transport?

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Update Pädiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Paediatric Nephrology in Africa

The Expansion of Pediatric Care Through Digital Technology

True Resilience: A Look Inside COVID’s Effect on Children with Medical Complexity and Their Families

Newest Diabetes-Related Technologies for Pediatric Type 1 Diabetes and Its Impact on Routine Care: a Narrative Synthesis of the Literature

Short-term Cardiovascular Complications of Multi-system Inflammatory Syndrome in Children (MIS-C) in Adolescents and Children

Obesity in Children with Kidney Disease

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Reanimation bei Kindern – besser vor Ort oder während Transport?

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Update Pädiatrie